Writing on product systems, fintech infrastructure, market behavior, and leadership lessons from practical execution.
📚 Books
Beyond platform leadership and infrastructure design, I write about trading psychology, financial literacy, and structured market participation.
Both books are published globally on Amazon (Kindle & Paperback editions available).
🟦 The Mind Game of Trading
Mastering Psychology for Consistent Profits
By Sreenivasulu Malkari
Overview
Trading success is rarely limited by strategy. It is limited by psychology.
In The Mind Game of Trading, I distill 15+ years of real-world trading experience into a structured framework for mastering discipline, emotional control, and execution integrity.
The book focuses on:
• Identifying hidden cognitive biases
• Structured journaling & checklist systems
• Emotional risk management
• Practical trading plan templates
• Long-term consistency frameworks
This is not a theory book — it is a practical discipline manual for traders at all levels.
🔗 Available on Amazon (Paperback & Kindle)
👉 https://www.amazon.com/dp/B0FNKGB7W2
🟦 The Stock Market Starter Kit
Learn to Trade Smart in 7 Days
By Sreenivasulu Malkari
Overview
Designed for beginners entering the Indian stock market, this book simplifies complex concepts into a structured 7-day learning framework.
It emphasizes structured thinking, capital protection, and long-term consistency as the core pillars of intelligent market participation.
It covers:
• How stock markets function (NSE/BSE context)
• Intraday, swing & long-term trading basics
• Risk management principles
• Chart reading fundamentals
• Practical checklists and action plans
Clear. Structured. Actionable.
🔗 Available on Amazon (Paperback & Kindle)
👉 https://www.amazon.com/dp/B0FF2NK8MV
-
LIC Q2 Review: ICICI Securities Maintains ‘Buy’ Call, Sees 23% Upside – Check Target Price
LIC Q2 Review: ICICI Securities Maintains ‘Buy’ Call, Sees 23% Upside – Check Target Price Life Insurance Corporation of India (LIC) has witnessed a significant growth in its annual premium equivalent (APE) in the first half of FY26, with a 3.6% year-on-year (YoY) increase. The company’s strategic initiatives have also tracked well consistently, leading ICICI…
-
GSK Pharma Q2 Review: Understanding the Temporary Hiccups and Their Impact on Indian Investors
GSK Pharma Q2 Review: A Closer Look at the Numbers GlaxoSmithKline Pharmaceuticals Ltd. recently reported its Q2 results, which showed a decline in revenue on a year-over-year (YoY) basis. This decline can be attributed to certain one-time events such as the GST transition and the fire incident at GSK Pharma’s contract manufacturing facility. Despite the…
-
Piramal Finance Relists On Stock Exchanges At 12% Premium
Piramal Finance Relists On Stock Exchanges At 12% Premium Piramal Finance, a wholly-owned subsidiary of Piramal Enterprises, has relisted on the stock exchanges at a 12% premium. The shares debuted at Rs 1,260 per share on the NSE, compared to the discovered price of Rs 1,124.20. As of 10:50 a.m., the shares were trading 17.59%…
-
MAS Financial Q2 Results: Axis Securities Reiterates ‘Buy’ Call, Expects Strong Growth
MAS Financial Q2 Review: Strong Growth Prospects Ahead MAS Financial Services Ltd. has reported its Q2 results, and Axis Securities has reiterated its ‘Buy’ call on the stock. The brokerage firm expects strong growth prospects for the company, driven by a robust distribution network and adequate capitalization. The stock currently trades at 1.7x FY27E BV,…
-
Motilal Oswal Downgrades Updater Services To ‘Neutral’ Amid Guidance Cuts, Near-Term Headwinds
Motilal Oswal Downgrades Updater Services To ‘Neutral’ Amid Guidance Cuts, Near-Term Headwinds Updater Services Ltd. recently reported its Q2 FY26 results, which fell short of expectations. The company’s revenue grew 7% year-over-year (YoY) to Rs 7.3 billion, below the estimated Rs 7.7 billion. The core Ebitda margin came in at 4.3%, down 130 basis points…
-
Zydus Lifesciences Q2 Review: ICICI Securities Retains ‘Hold’ Rating with Revised Target Price
Zydus Lifesciences Q2 Review: A Mixed Bag for Investors Zydus Lifesciences Ltd. recently announced its Q2 FY26 results, which were a mixed bag for investors. While the company’s revenue beat estimates, its margins were subdued due to the lower revenue of gRevlimid and the impact of recent acquisitions in the consumer wellness and medtech divisions.…